For a diabetes II patient of 70 kg in weight, 6 mg of insulin@ZIF-8 are needed on a daily ca. basis. As follows, this amount is well below the 30 µg mL-1 threshold for ZIF-8 (that is the ~38 mg threshold for the insulin@ZIF-8 biocomposite): Fig. A1 MTT cell viability of Raw 264.7 and 3T3 cells after 5 days exposure to various – amounts of 2-methylimidazole (2-mIM). Fig. A2 Fluorescence images detecting ROS production in MG-63 cells at different ZIF-8 – concentrations. Fig. A3 Fluorescence activated cell sorting analysis for MG-63 cells after three days – incubation with (a) 0 µg mL-1, (b) 30 µg mL-1, and (c) 100 µg mL-1 of ZIF-8. Fig. A4 Cell cycle analysis of six different cell lines, indicating cell population present in – the G2 / M stage at different ZIF-8 concentrations.
For a diabetes II patient of 70 kg in weight, ca. 6 mg of insulin@ZIF-8 are needed on a daily basis. As follows, this amount is well below the 30 µg mL-1 threshold for ZIF-8 (that is the ~38 mg threshold for the insulin@ZIF-8 biocomposite): Fig. A1 – MTT cell viability of Raw 264.7 and 3T3 cells after 5 days exposure to various amounts of 2-methylimidazole (2-mIM). Fig. A2 – Fluorescence images detecting ROS production in MG-63 cells at different ZIF-8 concentrations. Fig. A3 – Fluorescence activated cell sorting analysis for MG-63 cells after three days incubation with (a) 0 µg mL-1, (b) 30 µg mL-1, and (c) 100 µg mL-1 of ZIF-8. Fig. A4 – Cell cycle analysis of six different cell lines, indicating cell population present in the G2 / M stage at different ZIF-8 concentrations.
1-s2.0-S2352940717303839-mmc1.docx